Rong Zhou | AMiner学者主页

订阅小程序

旧版功能

开通会员低至0.73元/天

一次搞定AI科研

立即登录

English

联系方式

全面呈现 [Rong Zhou] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（3）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1EFFICACY AND SAFETY OF A 52 WEEK OPEN LABEL PHASE 2B EXTENSION TRIAL WITH MONTHLY DOSING OF AN ANTI-PCSK9 SMALL BINDING PROTEIN

Evan A. Stein,Traci Turner, Bain Butcher,Padma Mangu,Dean Kereiakes,Rong Zhou, Ran Fu,Tracy Mitchell

2020Journal of the American College of Cardiology（2020）引用：2

引用

AI阅读

2Safety, Tolerability and LDL-C Reduction with LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open-Label Extension Phase 2B Study

Evan A. Stein,Traci Turner,Dean J. Kereiakes, Bain Butcher,Padma Mangu,Rong Zhou

Introduction: LIB003 (LIB) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin which offers small injection volumes for monthly (Q4W) dosing. We evaluated l...

2019CIRCULATION（2019）引用：9

引用

AI阅读

3FRIEDEWALD FORMULA SIGNIFICANTLY UNDERESTIMATES LDL CHOLESTEROL COMPARED TO PREPARATIVE ULTRACENTRIFUGATION BELOW 70 MG/DL LEADING TO OVERESTIMATION OF THE LDL CHOLESTEROL REDUCTION FOR NEW DRUGS IN DEVELOPMENT

Evan A. Stein,Traci Turner,Nan Plunkett,Rong Zhou, Christine Fritz

Calculated LDL-C by Friedewald formula has been the basis for clinical and regulatory decision making for 40 years. The validity has recently been questioned as clinical guidelines and new therapeutic agents reduce LDL-C levels to below levels originally validated by Friedewald. We compare LDL-C by

2014Journal of the American College of Cardiology（2014）引用：7

引用

AI阅读